Lv3
270 积分 2021-09-01 加入
The challenges and strategies for treatment of hematological malignancies in China
3个月前
已完结
Development of peptide therapeutics: A nonclinical safety assessment perspective
5个月前
已完结
Targeting O-GlcNAcylation to develop novel therapeutics
6个月前
已完结
A timeline of biomarker changes before Alzheimer’s disease
6个月前
已完结
p53: A tale of complexity and context
7个月前
已完结
Insights into recent findings and clinical application of YAP and TAZ in cancer
7个月前
已完结
MA11.02 Targeting HER2 Exon 20–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor, Mobocertinib
2年前
已关闭
DZD9008, an oral, wild type selective EGFR inhibitor for the treatment of non-small-cell lung cancer with Exon20 insertion and other activating mutations
3年前
已关闭
TT01.03 Drug-Drug Interaction of Oral EGFR Inhibitor TAK-788 With Itraconazole and Rifampin in Healthy Volunteers
3年前
已完结
皖公网安备34019202002308
